Karen A. Cashmere - 12 Dec 2022 Form 4 Insider Report for ZyVersa Therapeutics, Inc. (ZVSA)

Role
Chief Commercial Officer
Signature
/s/ Peter Wolfe, attorney-in-fact for Karen A. Cashmere
Issuer symbol
ZVSA
Transactions as of
12 Dec 2022
Net transactions value
$0
Form type
4
Filing time
14 Dec 2022, 18:27:56 UTC
Next filing
18 Jul 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZVSA Stock Options (right to buy) Award $0 +9,927 $0.000000 9,927 12 Dec 2022 Common Stock 9,927 $5.03 Direct F1
transaction ZVSA Stock Options (right to buy) Award $0 +19,854 $0.000000 19,854 12 Dec 2022 Common Stock 19,854 $5.03 Direct F2
transaction ZVSA Stock Options (right to buy) Award $0 +29,781 $0.000000 29,781 12 Dec 2022 Common Stock 29,781 $11.58 Direct F3
transaction ZVSA Stock Options (right to buy) Award $0 +21,840 $0.000000 21,840 12 Dec 2022 Common Stock 21,840 $16.36 Direct F4
transaction ZVSA Stock Options (right to buy) Award $0 +21,840 $0.000000 21,840 12 Dec 2022 Common Stock 21,840 $16.36 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on September 10, 2014.
F2 100% of the option is immediately exercisable. The option vested in 4 equal annual installments commencing on October 30, 2017.
F3 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 2, 2020.
F4 The option vests in 3 equal annual installments commencing on February 8, 2022.
F5 The option vests in 3 equal annual installments commencing on January 28, 2023.